Showing 8621-8630 of 9652 results for "".
- New Isotretinoin Formulation Approvedhttps://practicaldermatology.com/news/20120529-new_isotretinoin_formulation_approved/2459794/A novel isotretinoin formulation for the treatment of severe recalcitrant nodular acne will soon be available from Ranbaxy. FDA approved Absorica (cis-isotretinoin), which
- New Retinoid Foam Wins FDA Approvalhttps://practicaldermatology.com/news/20120514-new_retinoid_foam_wins_fda_approval/2459805/The FDA has approved Fabior (tazarotene) Foam, 0.1%, for the treatment of acne vulgaris in patients 12 years and older. The approval was based on two multi-center, randomized, double-blind, vehicle-controlled pivotal Phase 3 studies, in which a total of 1,485 patients with moderate-to-severe acne vu
- Provectus Pharmaceuticals' PV-10 Phase 2 Final Data To Be Presentedhttps://practicaldermatology.com/news/20120509-provectus_pharmaceuticals_pv-10_phase_2_final_data_to_be_presented/2459806/Phase 2 final data on PV-10 for metastatic melanoma by Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) will be presented at the second European PostASCO Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanom
- Novartis Acquires Fougera Pharma for $1.5 Billionhttps://practicaldermatology.com/news/20120504-novartis_acquires_fougera_pharma_for_15_billion/2459809/With it's $1.5 billion acquisition of US-based Fougera Pharmaceuticals, Novartis will be the biggest maker of dermatologic generics in the country. The Fougera products will add to those of Novartis's existing generics unit Sandoz.
- Mylan, Impax Win Ruling in Doryx Generics Patent Casehttps://practicaldermatology.com/news/20120502-mylan_impax_win_ruling_in_doryx_generics_patent_case/2459810/Mylan Inc. (MYL) said it began selling a generic version of the antibiotic Doryx today after a judge ruled it didn't infringe a patent held by Warner Chilcott (WCRX) Plc.
- Ouchless Needle Announces First Exclusive International Distribution Agreement with Device Technologieshttps://practicaldermatology.com/news/20120501-ouchless_needle_announces_first_exclusive_international_distribution_agreement_with_device_technologies/2459811/Ouchless Needle by the BellaNovus Development Company announced their first international exclusive distribution agreement with Device Technologies for Australia and New Zealand. Developed by aesthetic plastic surgery innovator Marc J. Sa
- PreCision Dermatology Acquires Assets of Triax Pharmaceuticalshttps://practicaldermatology.com/news/20120430-precision_dermatology_acquires_assets_of_triax_pharmaceuticals/2459813/PreCision Dermatology has acquired the assets of Triax Pharmaceuticals LLC, a specialty pharmaceutical company with products including the mid-potency topical steroid Locoid, as well as Minocin and Tretin-X. Onset Dermatologics, the prescrip
- Enrollments Complete for Two Phase 2 ALA-PDT AK Trialshttps://practicaldermatology.com/news/20120424-enrollments_complete_for_two_phase_2_ala-pdt_ak_trials/2459815/DUSA Pharmaceuticals (NASDAQ GM: DUSA) completed patient enrollment in its Phase 2 clinical trial studying the broad area application with 1-, 2-, and 3-hour drug incubation for the treatment of actinic keratoses (AKs) of the face or scalp
- Efficacy Data for LaViv Now Publishedhttps://practicaldermatology.com/news/20120418-efficacy_data_for_laviv_now_published/2459822/Data demonstrating that LaViv (azficel-T, Fibrocell Science, Inc.) is effective for the aesthetic improvement of moderate to severe smile lines are now published online in Dermatologic Surgery. The combined results of two identically-designed, Phase III, multi-
- Lumenis Unveiling New Laser Capability at ASLMShttps://practicaldermatology.com/news/20120413-lumenis_unveiling_new_laser_capability_at_aslms/2459826/Lumenis will unveil UltraPulse's new SCAAR FX CO2 laser treatment capability at the American Society for Laser Medicine and Surgery (ASLMS) annual meeting in Kissimmee, FL. Using up to 150mJoules per pulse, the high energy impact and precision o